Geographic distribution of cervical cancer-associated human leucocyte antigens and cervical cancer incidence in Finland

International Journal of STD and AIDS

Volumn 18, Issue 10, 2007, Pages 672-679

  Castro, Felipe A ^a   Haimila, Katri ^b   Pasanen, Kari ^a,c   Kaasila, Marjo ^a   Patama, Toni ^a,c   Partanen, Jukka ^b   Surcel, Heljä Marja ^a   Pukkala, Eero ^d,e   Lehtinen, Matti ^e  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b FINNISH RED CROSS BLOOD SERVICE   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

^e UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Cervical cancer; Geography; Human leucocyte antigen; Human papillomavirus; Meta analysis

Indexed keywords

HLA A11 ANTIGEN; HLA ANTIGEN; HLA B15 ANTIGEN; HLA B7 ANTIGEN; HLA DR2 ANTIGEN; HLA DR6 ANTIGEN; TUMOR ANTIGEN; ANTIGEN;

ARTICLE; CANCER INCIDENCE; CANCER SUSCEPTIBILITY; CAUCASIAN; FINLAND; GENE FREQUENCY; GEOGRAPHIC DISTRIBUTION; HUMAN; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; ADOLESCENT; ADULT; DISEASE PREDISPOSITION; FEMALE; GENETICS; GEOGRAPHY; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; NEOPLASM; PAPILLOMA VIRUS; UTERINE CERVIX TUMOR;

ADOLESCENT; ADULT; ANTIGENS; DISEASE SUSCEPTIBILITY; FEMALE; FINLAND; GENE FREQUENCY; GEOGRAPHY; HLA ANTIGENS; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASMS; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS;

EID: 38449097343     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646207782193803     Document Type: Article

References (43)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(Suppl 8):S4-66
2. Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8
3. Moscicki AB, Schiffmann M, Kjaer S, Villa LL. Updating the natural history of HPV and anogenital cancer. Vaccine 2006;S24:42-51
4. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-71
5. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500-10
6. Bavinck JN, Gissmann L, Claas FH, et al. Relation between skin cancer, humoral responses to human papillomaviruses, and HLA class II molecules in renal transplant recipients. J Immunol 1993;151:1579-86
7. Hoglund P, Karre K, Klein G. The uterine cervix - a new member of the family of immunologically exceptional sites? Cancer Immunol 2003;3:6
8. Yang YC, Chang TY, Lee YJ, et al. HLA-DRB1 alleles and cervical squamous cell carcinoma: experimental study and meta-analysis. Hum Immunol 2006;67:331-40
9. Chan DP, Cheung TH, Tam AO, et al. Risk association between human leukocyte antigen-A allele and high-risk human papillomavirus infection for cervical neoplasia in Chinese women. J Infect Dis 2005;192:1749-56
10. Chan PK, Cheung JL, Cheung TH, et al. HLA-B alleles, high-risk HPV infection and risk for cervical neoplasia in southern Chinese women. Int J Cancer 2006;118:1430-5
11. Beskow AH, Josefsson AM, Gyllensten UB. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer 2001;93:817-22
12. Madeleine MM, Brumback B, Cushing-Haugen KL, et al. Human leukocyte antigen class II and cervical cancer risk: a population-based study. J Infect Dis 2002;186:1565-74
13. Thursz MR, Thomas HC, Greenwood BM, Hill AV. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet 1997;17:11-12
14. Kaslow RA, Rivers C, Tang J, et al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J Virol 2001;75:8681-9
15. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999;283:1748-52
16. Wang SS, Hildesheim A, Gao X, et al. Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies. J Infect Dis 2002;186:598-605
17. Siren MK, Sareneva H, Lokki ML, Koskimies S. Unique HLA antigen frequencies in the Finnish population. Tissue Antigens 1996;48:703-7
18. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365-9
19. Anttila A, Pukkala E, Soderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999;83:59-65
20. Glew SS, Duggan-Keen M, Ghosh AK, et al. Lack of association of HLA polymorphisms with human papillomavirus-related cervical cancer. Hum Immunol 1993;37:157-64
21. Duggan-Keen MF, Keating PJ, Stevens FR, et al. Immunogenetic factors in HPV-associated cervical cancer: influence on disease progression. Eur J Immunogenet 1996;23:275-84
22. Allen M, Kalantari M, Ylitalo N, et al. HLA DQ-DR haplotype and susceptibility to cervical carcinoma: indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. Tissue Antigens 1996;48:32-7
23. Sastre-Garau X, Loste MN, Vincent-Salomon A, et al. Decreased frequency of HLA-DRB1 13 alleles in French women with HPV-positive carcinoma of the cervix. Int J Cancer 1996;69:159-64
24. Montoya L, Saiz I, Rey G, Vela F, Clerici-Larradet N. Cervical carcinoma: human papillomavirus infection and HLA-associated risk factors in the Spanish population. Eur J Immunogenet 1998;25:329-37
25. Krul EJ, Schipper RF, Schreuder GM, Fleuren GJ, Kenter GG, Melief CJ. HLA and susceptibility to cervical neoplasia. Hum Immunol 1999;60:337-42
26. Maciag PC, Schlecht NF, Souza PS, Franco EL, Villa LL, Petzl-Erler ML. Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. Cancer Epidemiol Biomarkers Prev 2000;9:1183-91
27. Cuzick J, Terry G, Ho L, et al. Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women. Br J Cancer 2000;82:1348-52
28. Lin P, Koutsky LA, Critchlow CW, et al. HLA class II DR-DQ and increased risk of cervical cancer among Senegalese women. Cancer Epidemiol Biomarkers Prev 2001;10:1037-45
29. Dehaghani AS, Amirzargar A, Farjadian S, Ghaderi A. HLA-DQBl alleles and susceptibility to cervical squamous cell carcinoma in southern Iranian patients. Pathol Oncol Res 2002;8:58-61
30. Matsumoto K, Yasugi T, Nakagawa S, et al. Human papillomavirus type 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer. Int J Cancer 2003;106:919-22
31. Zehbe I, Mytilineos J, Wikstrom I, Henriksen R, Edler L, Tommasino M. Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol 2003;64:538-42
32. Magnusson PK, Lichtenstein P, Gyllensten UB. Heritability of cervical tumours. Int J Cancer 2000;88:698-701
33. Magnusson PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature 1999;400:29-30
34. Hemminki K, Dong C, Vaittinen P. Familial risks in cervical cancer: is there a hereditary component? Int J Cancer 1999;82:775-81
35. Hemminki K, Li X, Mutanen P. Familial risks in invasive and in situ cervical cancer by histological type. Eur J Cancer Prev 2001;10:83-9
36. Hemminki K, Li X, Vaittinen P. Time trends in the incidence of cervical and other genital squamous cell carcinomas and adenocarcinomas in Sweden, 1958-1996. Eur J Obstet Gynecol Reprod Biol 2002;101:64-9
37. Pukkala E, Weiderpass E. Time trends in socio-economic differences in incidence rates of cancers of the breast and female genital organs (Finland, 1971-1995). Int J Cancer 1999;81:56-61
38. Lipsitch M, Bergstrom CT, Antia R. Effect of human leukocyte antigen heterozygosity on infectious disease outcome: the need for allele-specific measures. BMC Med Genet 2003;4:2
39. Lehtinen M, Apter D, Dubin G, et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 2006;17:517-21
40. Sanjeevi CB, Hjelmstrom P, Hallmans G, et al. Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. Int J Cancer 1996;68:409-14
41. Haavio-Mannila E, Kuusi E, Kontula O. Trends in sexual life Working papers E. Helsinki: The Population Research Institute, 2001
42. Laukkanen P, Koskela P, Pukkala E, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003;84:2105-9
43. Lehtinen M, Kaasila M, Pasanen K, et al. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer 2006;119:2612-19